3 active not recruiting, 3 completed, 2 recruiting, 2 terminated. 11 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Active not recruiting 3, Completed 3, Recruiting 2, Terminated 2, Not yet recruiting 1 |
| Phase 1 | 3 | Terminated 2, Active not recruiting 1 |
Follow Philadelphia Chromosome Positive: new trials by email Literature Review of Philadelphia Chromosome Positive trials Research Report on Philadelphia Chromosome Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Blinatumomab, olverembatinib - Phase II Clinical Trial, Blinatumomab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2027-01-27 | 2026-10-07 |
| ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase Dasatinib, Decitabine and Cedazuridine - Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 39 | 2021-10-21 | 2026-10-02 |
| Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia Blinatumomab, Laboratory Biomarker Analysis, Pembrolizumab - CD19 Positive, Philadelphia Chromosome Positive | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 36 | 2019-08-02 | 2025-05-30 |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers Cladribine, Cytarabine, Dexrazoxane Hydrochloride - Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 100 | 2018-09-19 | 2026-11-10 |
| ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia ADCT-602 - Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 37 | 2018-08-24 | 2025-12-12 |
| Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Dexamethasone, Ponatinib Hydrochloride, Rituximab - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2018-06-26 | 2025-05-08 |
| Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia Blinatumomab, Cytarabine, Methotrexate - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 90 | 2017-11-29 | 2026-11-10 |
| Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia Blinatumomab, Ibrutinib - Adult B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive | Phase 2 | Completed | University of California, Davis | 19 | 2017-06-27 | 2026-06-09 |
| Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease Blinatumomab, TKI - Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 37 | 2015-09-14 | 2026-09-25 |
| Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Dexamethasone - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 88 | 2011-10-05 | 2026-10-06 |
| Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. Cyclophosphamide, Cytarabine, Dasatinib - Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression | Phase 2 | Completed | M.D. Anderson Cancer Center | 107 | 2006-09-28 | 2025-02-17 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Blast Crisis (5) · Burkitt Lymphoma (3) · Leukemia, Myeloid, Accelerated Phase (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myeloid, Chronic-Phase (1) · Myeloproliferative Disorders (1) · Neoplasm, Residual (1) · Sarcoma, Myeloid (1)
Hemic and Lymphatic Diseases (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9) · Lymphoproliferative Disorders (9) · Hematologic Diseases (8) · Leukemia (8) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Bone Marrow Diseases (6) · Chronic Disease (6) · Disease Attributes (6) · Leukemia, Lymphoid (6)
blinatumomab (5) · Cytarabine (4) · N,N-dicyclohexyl-isoborneol-10-sulfonamide (4) · Calcium Dobesilate (3) · Dexamethasone (3) · Methotrexate (3) · auricularum (3) · dexamethasone 21-phosphate (3) · dexamethasone acetate (3) · merphos (3) · ponatinib (3) · CT-P10 (2) · Cyclophosphamide (2) · Dasatinib (2) · Doxorubicin (2)
M.D. Anderson Cancer Center (9) · City of Hope Medical Center (1) · University of California, Davis (1)
United States (11)
Elias Jabbour (4) · Brian Jonas (1) · Elias J Jabbour, MD (1) · Farhad Ravandi-Kashani (1) · Farhad Ravandi-Kashani, MD (1) · Lihua Budde (1) · Maro Ohanian (1) · Nitin Jain (1)
PMID 35622074, PMID 41671463, PMID 20466853, PMID 26432046, PMID 30501869, PMID 35713551, PMID 36402146, PMID 36600670, PMID 38324336, PMID 39028925, PMID 40369607
P30CA016672 (1), P30CA093373 (1)